Investor Ideas #Potcasts
545, #Cannabis News and #Stocks on the Move; (OTCQB: $ALID) (OTC: $LRSV), (CSE: $RAMM.C) (OTC: $RAMMF),
(TSX: $ZENA.TO)
Delta, Kelowna, BC, March 25, 2021 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/032521-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/03251ALID-LRSV-RAMM-ZENA.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public company announcements.
Allied
Corp. (OTCQB:
ALID) an international medical company focused on creating
and providing health solutions to address today’s medical mental health issues announced that it
has successfully filed for trademark protection for its pharmaceutical product
“PSILONEX.”
PSILONEX is a proprietary
formulation prescribed within a treatment path that involves both
a pharmaceutical psilocybin-based
formulation, followed by a daily cannabinoid maintenance period. PSILONEX is
intended to be prescribed by a physician as “PSILONEX Rx,” followed by the cannabinoid daily therapy that can be
purchased by the consumer in regions where it is legal to do so as “PSILONEX Daily,” Both of these products
are currently being researched, developed and tested by Allied’s pharmaceutical
development team.
The filed trademark protects
Allied’s intellectual property for PSILONEX covering: chemical preparations for
pharmaceutical or medical purposes, namely, for treating depression, anxiety,
and PTSD, and for improving mental health; Nutraceuticals for the treatment of
mental health disorders and conditions, including depression, anxiety, and
PTSD; Nutraceuticals for use as a dietary supplement; Nutraceuticals for use as
a dietary supplement for improving mental health; Pharmaceutical preparations
and substances for the treatment of psychiatric diseases and disorders;
Pharmaceutical preparations for the treatment and prevention of mental health
disorders; Pharmaceuticals, namely, psychotropics; Dietary and nutritional
supplements; Fungal extracts sold as a component ingredient of nutritional
supplements and vitamins; Providing a website featuring information in the
field of mental health and physical health, including living a healthy and
disease-free life; Providing a website featuring information about health,
wellness and nutrition; and Providing a website featuring information
concerning alternative health and healing.
Link
Reservations Inc. (OTC:
LRSV), a provider of wellness and cannabidiol (CBD)
products for both humans and pets, announced that
the company is preparing to launch its first functional mushroom product,
DailyLife CBD Immune. The new tincture product, tailored for people, will
feature both CBD and a wide spectrum of functional mushrooms (including Lion's
Mane) which help boost the immune system.
"This is an exciting first step
for the Company and we are thrilled to soon bring to market our first CBD
mushroom product. Our focus has always been on providing high quality products
that can help people benefit from the power of natural ingredients, and that is
what we have aimed for with this product," commented Rene Lauritsen, Link
Reservations Inc CEO. "Understandably, people are focusing on their health
now more than ever and looking for ways in which they can boost their immunity,
particularly in a natural way. Our goal is to fully satisfy their need with
this new product. We have been researching the benefits of functional mushrooms
for the past few months and have developed a product that will harness their
power," added Lauritsen.
As the world continues to reel from
the Coronavirus pandemic, and learns to live with the virus, many people are
focusing on different ways to boost their immune system. According to Rick
Miller, Associate Director of Food & Drink Specialised Nutrition at Mintel,
the majority of consumers in Europe purchase vitamins, minerals and supplements
that strengthen the immune system, while in the US, 35% of consumers think
products that support the immune health would motivate them when making a
purchase.
DailyLife CBD Immune will feature an
organic blend of 13 different medicinal mushrooms, including Lion's Mane,
Turkey Tail, Chaga, Red Reishi and Cordyceps, amongst others. By focusing on a
variety of mushrooms the product is able to encompass multiple immune boosting
traits and benefits. In addition, DailyLife CBD Immune also includes 250mg of
hemp oil CBD extract and 100mg of vitamin C, which will add to the immune
boosting benefits.
"We are confident that this
product and our future ones will have a very warm reception in the market, and
we look forward to sharing more developments as they arise through press
releases," ended Lauritsen.
For more information about
DailyLifeCBD please visit: https://dailylifecbd.com/.
DailyLifeCBD is sister brand to
LinkResPet, a website focused on providing CBD pet products for dogs, cats and
horses. For more information about LinkResPet, please visit www.linkrespet.com or
follow them on Twitter on @res_pet
RAMM Pharma Corp. (CSE:
RAMM) (OTC:
RAMMF), a leader in plant-derived cannabinoid pharmaceutical
products, announced that it
has initiated clinical trials studying the efficacy of its proprietary
NettaVet™ pet cannabinoid formulation for the treatment of four pathologies in
animals. The trials will be conducted in partnership with Universidad de la
Republica de Uruguay in collaboration with leading international experts at
Montreal University (Canada), University of Buenos Aires (Argentina), São Paulo
State University (Brazil) and University of Barcelona (Spain). NettaLife is a
wholly owned subsidiary of RAMM, dedicated to the production, export and
commercialization of pet products, food, pharmaceutical specialties and
cosmetic products for animals. More information can be found on NettaLife’s
website www.nettalife.com.
The
clinical trials will evaluate the efficacy of NettaVet™ cannabinoid
formulations for the treatment of the following pathologies:
● Chronic
Osteoarthritis pain in dogs (Cannis familiaris)
● Chronic
Osteoarthritis pain in horses (Equus caballus)
● Allergic
Dermatitis in dogs (Cannis familiaris)
●
Anxiety in dogs (Cannis familiaris)
Prof.
Dr. Nadia Crosignani, MSc., PhD (UdelaR, Uruguay), lead advisor for the
clinical trials stated, “We are, from an academic stand point, very excited to
be able to conduct these clinical trials together with RAMM Pharma and the
prospects for these novel treatments to improve the quality life of animals.”
“We are
pleased to commence this initial set of clinical trials with renowned experts
to advance the development of products to help address some of the most common
animal ailments,” stated Jack Burnett, Chief Executive Officer.
The
NettaVet™ team is developing a line of specialized CBD veterinary and medicinal
products for animals. CBD has shown benefits in animals including pain and
inflammation reduction, immune system improvement, skin and fur care and
cognitive support. NettaVet™ products will offer a natural, holistic medical
alternative for animal care and which we believe may produce therapeutic
results for diagnosed conditions such as Idiopathic epilepsy, canine lymphoma
and anxiety, without the negative side effects of traditional veterinary
medications. CBD is renowned as a very well-tolerated medication and
nutraceutical that doesn't produce harmful side effects. In addition, CBD-based
products are believed not to damage the kidneys, liver or gastrointestinal
system. This business line will synergistically leverage RAMM’s pharmaceutical
expertise to continue to further the development of its products which will
begin being rolled out in 2021.
Zenabis Global Inc.
(TSX:
ZENA) announced the
launch of pre-roll multipacks as well as new distribution agreements.
Zenabis'
continues to expand on the popularity of its value-oriented Re-Up portfolio
with the launch of its new 10 and 20, Multi-Pack Indica and Sativa 0.5g
Pre-Roll formats. This unique, multi-pack will be available initally in Quebec
and Alberta in the larger, 20-pack format in early April with national rollout
of both formats expected to be in time for the 4/20 celebrations. The full
impact of the launch is expected to be reflected in Zenabis's Q2 2021 results.
Zenabis'
multipack pre-roll offering will serve consumers seeking better value for money
and larger package sizes to reduce the frequency of purchases. These new
products build on the success of Zenabis popular 28g Re-Up Indica / Sativa
products. The launch of the 10 / 20
Multi-Pack Pre-Roll format underpins Zenabis strategy of leveraging its
ability to deliver the quality and affordability expected by its loyal customer
base while delivering on the top and bottom line performance anticipated by
shareholders.
Zenabis
is also excited to announce that it has concluded agreements with Cannabis NL
(Newfoundland and Labrador) and the government of Nunavut, completing its goal
of extending the availability of its Namaste and Re-Up products to all Canadian
provinces and territories. Shipments under these new agreements commence in
April. Zenabis joins a small, select
group of Canadian LPs whose product quality and value have been recognized as a
must-have, on-shelf product by every Provincial & Territorial Board in
Canada. These new agreements further cement Zenabis as one of the top
recreational LP's in the country.
"Finalizing
agreements with Cannabis NL and the government of Nunavut, which means making
good on our promise of making our Namaste and Re-Up brands available from
coast-to-coast-to-coast, is a benchmark moment for this organization. We
continue to portray what a lean, nimble company that grows really, really good
cannabis can achieve. The addition of
the pre-roll multipack to our assortment builds on Re-Up's brand purpose of
providing affordable, high-THC products to our value-oriented customers"
stated Robert Maxwell, Zenabis' Vice President, Sales and Marketing.
Investor
ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and that this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment.
Learn
more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To
hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google Play
Music and most audio platforms available.
Potcasts
is now a certified word mark Trademark on the blockchain through Cognate, Inc.
CM Certification-Registration Number: 10468217708
Investors can trade these stocks and other ideas on our site using our list of top stock trading
apps including Robinhood , Acorn, Stash and others.
About
Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. LRSV
is a frequent paid client for our news publishing service
Contact management and IR of each company
directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to
regulations of each country. Please read Investorideas.com privacy
policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
No comments:
Post a Comment